

Triclabendazole / Abamectin Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 5341824-00010 2.8 30.09.2023 Date of first issue: 05.12.2019

1. PRODUCT AND COMPANY IDENTIFICATION

Triclabendazole / Abamectin Formulation Product name

Manufacturer or supplier's details

Company : MSD

Address 50 Tuas West Drive

Singapore - Singapore 638408

Telephone +1-908-740-4000

Emergency telephone number : 65 6697 2111 (24/7/365)

E-mail address EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use Veterinary product Restrictions on use Not applicable

2. HAZARDS IDENTIFICATION

GHS Classification

repeated exposure (Oral)

Specific target organ toxicity - : Category 2 (Liver, Blood)

Short-term (acute) aquatic

hazard

Category 1

Long-term (chronic) aquatic

hazard

Category 1

GHS label elements

Hazard pictograms



Signal word

Hazard statements H373 May cause damage to organs (Liver, Blood) through pro-

longed or repeated exposure if swallowed.

H410 Very toxic to aquatic life with long lasting effects.

Precautionary statements Prevention:

P260 Do not breathe mist or vapours.



Triclabendazole / Abamectin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 2.8
 30.09.2023
 5341824-00010
 Date of first issue: 05.12.2019

P273 Avoid release to the environment.

Response:

P314 Get medical advice/ attention if you feel unwell.

P391 Collect spillage.

Disposal:

P501 Dispose of contents/ container to an approved waste

disposal plant.

Other hazards which do not result in classification

None known.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Triclabendazole	68786-66-3	>= 10 -< 20
abamectin (combination of avermectin B1a and	71751-41-2	>= 0.0025 -< 0.025
avermectin B1b) (ISO)		

4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled : If inhaled, remove to fresh air.

Get medical attention if symptoms occur.

In case of skin contact : Wash with water and soap as a precaution.

Get medical attention if symptoms occur. Flush eyes with water as a precaution.

Get medical attention if irritation develops and persists.

: If swallowed, DO NOT induce vomiting.

Get medical attention if symptoms occur.

Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and

In case of eye contact

delayed

If swallowed

May cause damage to organs through prolonged or repeated

exposure if swallowed.

Protection of first-aiders : First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

5. FIREFIGHTING MEASURES

Suitable extinguishing media : Water spray

Alcohol-resistant foam



Triclabendazole / Abamectin Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 2.8 30.09.2023 5341824-00010 Date of first issue: 05.12.2019

Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

Specific hazards during fire-

fighting

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod-

ucts

Carbon oxides

Nitrogen oxides (NOx)

Metal oxides

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

Special protective equipment :

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protec- :

tive equipment and emer-

gency procedures

Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so.

Prevent spreading over a wide area (e.g. by containment or oil

barriers).

Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up

Soak up with inert absorbent material.

For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absor-

bent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

7. HANDLING AND STORAGE

Technical measures : See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation Advice on safe handling

Use only with adequate ventilation.

Do not breathe mist or vapours.



Triclabendazole / Abamectin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 2.8
 30.09.2023
 5341824-00010
 Date of first issue: 05.12.2019

Do not swallow.

Avoid contact with eyes.

Avoid prolonged or repeated contact with skin.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Take care to prevent spills, waste and minimize release to the

environment.

Conditions for safe storage : Keep in properly labelled containers.

Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:

Strong oxidizing agents

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis	
Triclabendazole	68786-66-3	TWA	30 μg/m3 (OEB 3)	Internal	
	Further information: DSEN				
		Wipe limit	100 μg/100 cm2	Internal	
abamectin (combination of avermectin B1a and avermec- tin B1b) (ISO)	71751-41-2	TWA	15 μg/m3 (OEB 3)	Internal	
		Wipe limit	150 µg/100 cm ²	Internal	

Engineering measures : Use appropriate engineering controls and manufacturing

technologies to control airborne concentrations (e.g., drip-

less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to

protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face con-

tainment devices).

Minimize open handling.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection.

Filter type

: Particulates type

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles.



Triclabendazole / Abamectin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 2.8
 30.09.2023
 5341824-00010
 Date of first issue: 05.12.2019

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, dis-

posable suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

Hygiene measures : If exposure to chemical is likely during typical use, provide

eye flushing systems and safety showers close to the work-

ing place.

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : suspension

Colour : white

Odour : No data available

Odour Threshold : No data available

pH : 5.0 - 7.0

Melting point/freezing point : < 5 °C

Initial boiling point and boiling

range

No data available

Flash point : No data available

Evaporation rate : No data available

Flammability (solid, gas) : Not applicable

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower :

flammability limit

No data available



Triclabendazole / Abamectin Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 2.8 30.09.2023 5341824-00010 Date of first issue: 05.12.2019

Vapour pressure : No data available

Relative vapour density : No data available

Relative density : No data available

Density : 1,050 - 1,080 g/cm³ (20 °C)

Solubility(ies)

Water solubility : soluble

Partition coefficient: n-

octanol/water

Not applicable

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle size : Not applicable

10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.
Chemical stability : Stable under normal conditions.
Possibility of hazardous reac- : Can react with strong oxidizing agents.

tions

: None known.

Conditions to avoid Incompatible materials

Oxidizing agents

Hazardous decomposition

No hazardous decomposition products are known.

products

11. TOXICOLOGICAL INFORMATION

Information on likely routes of:

exposure

Inhalation Skin contact Ingestion Eye contact

Acute toxicity

Not classified based on available information.



Triclabendazole / Abamectin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 2.8
 30.09.2023
 5341824-00010
 Date of first issue: 05.12.2019

Components:

Triclabendazole:

Acute oral toxicity : LD50 (Mouse): > 8,000 mg/kg

LD50 (Rabbit): 206 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 0.5 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Assessment: The substance or mixture has no acute inhala-

tion toxicity

Acute dermal toxicity : LD50 (Rat): > 4,000 mg/kg

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Acute oral toxicity : LD50 (Rat): 24 mg/kg

LD50 (Mouse): 10 mg/kg

LDLo (Monkey): 24 mg/kg

Symptoms: Dilatation of the pupil

Acute inhalation toxicity : LC50 (Rat): 0.023 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rat): 330 mg/kg

LD50 (Rabbit): 2,000 mg/kg

Skin corrosion/irritation

Not classified based on available information.

Components:

Triclabendazole:

Species : Rabbit

Result : Mild skin irritation

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Species : Rabbit

Result : No skin irritation

Serious eye damage/eye irritation

Not classified based on available information.



Triclabendazole / Abamectin Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 2.8 30.09.2023 5341824-00010 Date of first issue: 05.12.2019

Components:

Triclabendazole:

Species : Rabbit

Result : No eye irritation

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Species : Rabbit

Result : Mild eye irritation

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:

Triclabendazole:

Result : Not a skin sensitizer.

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Test Type : Maximisation Test Exposure routes : Skin contact

Result : Not a skin sensitizer.

Germ cell mutagenicity

Not classified based on available information.

Components:

Triclabendazole:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: DNA damage and repair, unscheduled DNA syn-

thesis in mammalian cells (in vitro)

Result: negative

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Test system: Chinese hamster lung cells

Result: negative

Test Type: Alkaline elution assay



Triclabendazole / Abamectin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 2.8
 30.09.2023
 5341824-00010
 Date of first issue: 05.12.2019

Result: negative

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow

cytogenetic test, chromosomal analysis)

Species: Mouse

Application Route: Intraperitoneal injection

Result: negative

Carcinogenicity

Not classified based on available information.

Components:

Triclabendazole:

Species : Mouse
Application Route : Oral
Exposure time : 2 Years
Result : negative

Species : Rat
Application Route : Oral
Exposure time : 2 Years
Result : negative

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Species : Rat
Application Route : Oral
Exposure time : 105 weeks
Result : negative

Species : Mouse
Application Route : Oral
Exposure time : 93 weeks
Result : negative

Reproductive toxicity

Not classified based on available information.

Components:

Triclabendazole:

Effects on fertility : Test Type: Fertility/early embryonic development

Application Route: Oral

Fertility: NOAEL: 50 mg/kg body weight

Result: No effects on fertility

Test Type: Fertility/early embryonic development

Application Route: Oral

Fertility: NOAEL: 50 mg/kg body weight

Result: No effects on fertility



Triclabendazole / Abamectin Formulation

Version SDS Number: Date of last issue: 04.04.2023 Revision Date: 2.8 30.09.2023 5341824-00010 Date of first issue: 05.12.2019

Test Type: Two-generation reproduction toxicity study

Species: Rat

Application Route: Oral

Fertility: NOAEL: 5.5 mg/kg body weight

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rat

Application Route: Oral

Developmental Toxicity: LOAEL: 200 mg/kg body weight

Result: Effects on foetal development

Test Type: Embryo-foetal development

Species: Rat

Application Route: Oral

Developmental Toxicity: NOAEL: 50 mg/kg body weight

Test Type: Embryo-foetal development

Species: Rabbit

Application Route: Oral

Developmental Toxicity: LOAEL: 10 mg/kg body weight

Result: Effects on foetal development Remarks: Maternal toxicity observed.

Test Type: Embryo-foetal development

Species: Rabbit Application Route: Oral

Developmental Toxicity: NOAEL: 3 mg/kg body weight

Remarks: Maternal toxicity observed.

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Effects on fertility Test Type: Fertility

> Species: Rat, male Application Route: Oral Result: Effects on fertility

Test Type: Two-generation reproduction toxicity study

Species: Rat

Application Route: Oral

Early Embryonic Development: NOAEL: 0.12 mg/kg body

weight

Result: Fetotoxicity

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Mouse

Application Route: Oral

General Toxicity Maternal: NOAEL: 0.05 mg/kg body weight Developmental Toxicity: NOAEL: 0.2 mg/kg body weight

Result: Cleft palate

Remarks: Adverse developmental effects were observed

Test Type: Embryo-foetal development

Species: Rabbit



Triclabendazole / Abamectin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 2.8
 30.09.2023
 5341824-00010
 Date of first issue: 05.12.2019

Application Route: Oral

Developmental Toxicity: LOAEL: 2 mg/kg body weight Result: Cleft palate, Teratogenic effects, Reduced embryonic

survival

Remarks: Adverse developmental effects were observed

Test Type: Development

Species: Rat

Application Route: Oral

Developmental Toxicity: LOAEL: 1.6 mg/kg body weight

Result: Teratogenic effects

Reproductive toxicity - As-

sessment

Some evidence of adverse effects on sexual function and fertility, based on animal experiments., Some evidence of

adverse effects on development, based on animal experi-

ments.

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

May cause damage to organs (Liver, Blood) through prolonged or repeated exposure if swallowed.

Components:

Triclabendazole:

Target Organs : Liver, Blood

Assessment : May cause damage to organs through prolonged or repeated

exposure.

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Exposure routes : Ingestion

Target Organs : Central nervous system

Assessment : Causes damage to organs through prolonged or repeated

exposure.

Repeated dose toxicity

Components:

Triclabendazole:

Species : Rat
NOAEL : 6.6 mg/kg
LOAEL : 69 mg/kg
Application Route : Oral
Exposure time : 13 Weeks
Target Organs : Blood

Species : Dog NOAEL : 3.4 mg/kg



Triclabendazole / Abamectin Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 2.8 30.09.2023 5341824-00010 Date of first issue: 05.12.2019

LOAEL : 37 mg/kg
Application Route : Oral
Exposure time : 13 Weeks
Target Organs : Liver, Blood

Species : Mouse
NOAEL : 29 mg/kg
Application Route : Oral
Exposure time : 24 Months
Target Organs : Liver

Species : Rat
NOAEL : 4 mg/kg
Application Route : Oral
Exposure time : 24 Months

Remarks : No significant adverse effects were reported

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Species : Rat
NOAEL : 1.5 mg/kg
Application Route : Oral
Exposure time : 24 Months

Target Organs : Central nervous system

Symptoms : Tremors, ataxia

Species : Mouse
NOAEL : 4.0 mg/kg
Application Route : Oral
Exposure time : 24 Months

Target Organs : Central nervous system

Symptoms : Tremors, ataxia

Species : Dog
NOAEL : 0.25 mg/kg
LOAEL : 0.5 mg/kg
Application Route : Oral
Exposure time : 53 Weeks

Target Organs : Central nervous system
Symptoms : Tremors, weight loss
Remarks : mortality observed

Species : Monkey
NOAEL : 1.0 mg/kg
Application Route : Oral
Exposure time : 14 Weeks

Target Organs : Central nervous system

Aspiration toxicity

Not classified based on available information.



Triclabendazole / Abamectin Formulation

Version SDS Number: Date of last issue: 04.04.2023 Revision Date: 2.8 30.09.2023 5341824-00010 Date of first issue: 05.12.2019

Experience with human exposure

Components:

Triclabendazole:

Ingestion Symptoms: Abdominal pain, Sweating, Headache, Nausea,

Vomiting, anorexia, Dizziness, Fatigue, Cough, Fever, pruritis

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Ingestion Symptoms: May cause, Tremors, Diarrhoea, central nervous

system effects, Salivation, tearing

12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Toxicity to fish LC50 (Oncorhynchus mykiss (rainbow trout)): 3.2 µg/l

Exposure time: 96 h

LC50 (Lepomis macrochirus (Bluegill sunfish)): 9.6 µg/l

Exposure time: 96 h

LC50 (Ictalurus punctatus (channel catfish)): 24 µg/l

Exposure time: 96 h

LC50 (Cyprinus carpio (Carp)): 42 µg/l

Exposure time: 96 h

LC50 (Cyprinodon variegatus (sheepshead minnow)): 15 µg/l

Exposure time: 96 h

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Americamysis): 0.022 µg/l

Exposure time: 96 h

EC50 (Daphnia magna (Water flea)): 0.34 μg/l

Exposure time: 48 h

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): 100

mg/l

Exposure time: 72 h

M-Factor (Acute aquatic tox-

icity)

10,000

Toxicity to fish (Chronic tox-

icity)

NOEC (Pimephales promelas (fathead minnow)): 0.52 µg/l

Exposure time: 32 d

Toxicity to daphnia and other : aquatic invertebrates (Chron-

ic toxicity)

NOEC (Daphnia magna (Water flea)): 0.03 µg/l

Exposure time: 21 d

NOEC (Mysidopsis bahia (opossum shrimp)): 0.0035 µg/l



Triclabendazole / Abamectin Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 2.8 30.09.2023 5341824-00010 Date of first issue: 05.12.2019

Exposure time: 28 d

M-Factor (Chronic aquatic

toxicity)

10,000

Toxicity to microorganisms

EC50: > 1,000 mg/l Exposure time: 3 h

Test Type: Respiration inhibition

Persistence and degradability

Components:

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Stability in water : Hydrolysis: 50 %(< 12 h)

Bioaccumulative potential

Components:

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Bioaccumulation : Bioconcentration factor (BCF): 52

Partition coefficient: n-

octanol/water

log Pow: 4

Mobility in soil

Components:

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Distribution among environ-

mental compartments

: log Koc: > 3.6

Other adverse effects

No data available

13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Do not dispose of waste into sewer.

Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

14. TRANSPORT INFORMATION

International Regulations

UNRTDG

UN number : UN 3082

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,



Triclabendazole / Abamectin Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 2.8 30.09.2023 5341824-00010 Date of first issue: 05.12.2019

N.O.S.

(abamectin (combination of avermectin B1a and avermectin

B1b) (ISO))

Class : 9
Packing group : III
Labels : 9
Environmentally hazardous : yes

IATA-DGR

UN/ID No. : UN 3082

Proper shipping name : Environmentally hazardous substance, liquid, n.o.s.

(abamectin (combination of avermectin B1a and avermectin

B1b) (ISO))

Class : 9 Packing group : III

Labels : Miscellaneous

Packing instruction (cargo : 964

aircraft)

Packing instruction (passen-

964

ger aircraft)

Environmentally hazardous : yes

IMDG-Code

UN number : UN 3082

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S.

(abamectin (combination of avermectin B1a and avermectin

B1b) (ISO))

Class : 9
Packing group : III
Labels : 9
EmS Code : F-A, S-F
Marine pollutant : yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

Workplace Safety and Health Act and Workplace Safety and Health (General Provisions) Regulations: This product is subjected to the SDS, labelling, PEL and other requirements in the Act/Regulations.

Environmental Protection and Management Act and

Environmental Protection and Management (Hazard-

Not applicable



Triclabendazole / Abamectin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 2.8
 30.09.2023
 5341824-00010
 Date of first issue: 05.12.2019

ous Substances) Regulations

Fire Safety (Petroleum and Flammable Materials) :

Regulations

: Not applicable

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

16. OTHER INFORMATION

Revision Date : 30.09.2023

Further information

Sources of key data used to

compile the Safety Data

Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

Date format : dd.mm.yyyy

Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association: IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evalua-



Triclabendazole / Abamectin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 2.8
 30.09.2023
 5341824-00010
 Date of first issue: 05.12.2019

tion, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

SG / EN